13301-04-7

Usage

Uses

Used in Organic Synthesis:
Methyl 3,6-dibromopyrazine-2-carboxylate is used as a building block in organic synthesis for the creation of heterocyclic compounds. Its presence of bromine atoms and ester functionality allows for various chemical reactions, making it a valuable component in the synthesis of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, methyl 3,6-dibromopyrazine-2-carboxylate is used as a starting material for the development of new drugs. Its potential antimicrobial and anticancer properties make it a promising candidate for drug discovery and development. Researchers can utilize its unique structure to design and synthesize novel therapeutic agents with improved efficacy and selectivity.
Used in Antimicrobial Applications:
Methyl 3,6-dibromopyrazine-2-carboxylate is used as an antimicrobial agent due to its ability to inhibit the growth of various microorganisms. Its bromine atoms and heterocyclic structure contribute to its antimicrobial activity, making it a potential candidate for the development of new antimicrobial drugs to combat drug-resistant infections.
Used in Anticancer Applications:
Methyl 3,6-dibromopyrazine-2-carboxylate is used as a potential anticancer agent due to its ability to target and inhibit the growth of cancer cells. Its unique chemical properties allow it to interfere with essential cellular processes, leading to the suppression of tumor growth and progression. Further research and development are needed to fully explore its potential as a therapeutic agent in cancer treatment.

InChI:InChI=1/C6H4Br2N2O2/c1-12-6(11)4-5(8)9-2-3(7)10-4/h2H,1H3

Upstream product

• 5424-01-1 3-aminopyrazinoic acid 
• 16298-03-6 Methyl 3-amino-2-pyrazinecarboxylate 
• 6966-01-4 methyl 3-amino-6-bromopyrazine-2-carboxylate 

Downstream Products

• 957230-68-1 3,6-dibromo-pyrazine-2-carboxylic Acid 
• 1093383-18-6 6-bromo-3-[(4-fluorophenyl)sulfanyl]pyrazine-2-carboxylic acid methyl ester 
• 1093383-19-7 3-bromo-6-[(4-fluorophenyl)sulfanyl]pyrazine-2-carboxylic acid methyl ester 
• 1093383-21-1 3,6-bis[(4-fluorophenyl)sulfanyl]pyrazine-2-carboxylic acid methyl ester 
• 1270497-52-3 3,6-dibromo-2-hydroxymethylpyrazine 
• 1270497-54-5 3,6-dibromopyrazine-2-yl-formaldehyde 
• 1313913-27-7 C₁₂H₁₀BrN₃O₃ 
• 1313913-56-2 C₂₃H₂₆N₆O₃ 
• 1313913-57-3 C₂₄H₂₉N₇O₃ 
• 1313913-58-4 C₂₃H₂₈N₆O₃ 
• 1313913-35-7 C₂₅H₂₈N₄O₅ 
• 1313913-36-8 C₂₄H₂₆N₄O₄ 
• 1313913-37-9 C₂₅H₂₉N₅O₄ 
• 1313913-38-0 C₂₄H₂₈N₄O₄ 

Relevant academic research and scientific papers

Aminopyrazinamides: Novel and specific GyrB inhibitors that kill replicating and nonreplicating mycobacterium tuberculosis

Aminopyrazinamides originated from a high throughput screen targeting the Mycobacterium smegmatis (Msm) GyrB ATPase. This series displays chemical tractability, robust structure-activity relationship, and potent antitubercular activity. The crystal structure of Msm GyrB in complex with one of the aminopyrazinamides revealed promising attributes of specificity against other broad spectrum pathogens and selectivity against eukaryotic kinases due to novel interactions at hydrophobic pocket, unlike other known GyrB inhibitors. The aminopyrazinamides display excellent mycobacterial kill under in vitro, intracellular, and hypoxic conditions.

JAK kinase inhibitor, preparation method thereof, and application in the field of medicines

The application relates to a JAK kinase inhibitor, a preparation method thereof, and an application in the field of medicines and belongs to the field of medical chemistry. In the application, a series of novel small-molecular JAK inhibitors are provided and are represented as the general formula (II). The compounds have better effects and higher safety in prevention or treatment on JAK-related adaptation diseases.

BCR-ABL kinase inhibitor and its application (by machine translation)

The present invention relates to the field of chemical medicines, in particular to compounds as represented by formula I having BCR-ABL kinase inhibitory activity, or pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug thereof, and pharmaceutical composition containing the compounds, and application of the compounds or compositions in drug preparation. The compounds of the present invention have strong inhibitory effect on BCR-ABL kinase, and can be used to treat diseases such as tumors.

Discovery of a series of imidazopyrazine small molecule inhibitors of the kinase MAPKAPK5, that show activity using in vitro and in vivo models of rheumatoid arthritis

MAPKAPK5 has been proposed to play a role in regulation of matrix metalloprotease expression and so to be a potential target for intervention in rheumatoid arthritis. We present here the identification of a series of compounds against this target which are effective in both biochemical and cell assays. The expansion of the series is described, along with early SAR and pharmacokinetics for some representative compounds.

INHIBITORS OF JAK

The present invention relates to the use of novel compounds of Formula I, wherein the variables m, n, p, q, Q, r, R, R′, X, X′, Y, Z1, Z2, and Z3 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.

Efficient three-step one-pot synthesis of a novel 2,3,5-substituted pyrazine library

The partnership between rational synthesis design and mass-triggered preparative LCMS is a powerful one, capable of furnishing very large libraries in a selective manner in a very short space of time. Herein, we communicate one example of possibly a perfect marriage between the synthetic chemistry and the subsequent purification method employed, affording a ～1000-member library supplying 50 mg on average of final compound in less than a month.